Bausch Health

BHC

Market cap $2.23B

LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7, 2025 (the "Shareholders Meeting"). At the Shareholders Meeting, shareholders of the Company approved the ratification, confirmation and approval of the adoption of the Company's Amended and Restated Shareholder Rights Plan Agreement dated April 14, 2025, as amended and restated on August 25, 2025 (the "Rights Plan Agreement"), as described in detail in the Company's Management Proxy Circular and Proxy Statement dated August 27, 2025.

The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appearance while enhancing natural beauty. LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, a global leader in the medical aesthetics market, will be featured on The Balancing Act, airing on Lifetime, in a special episode spotlighting its portfolio of non-invasive skin rejuvenation and tightening technologies: Thermage® FLX, Clear + Brilliant® and Fraxel FTX™.

LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will host a live conference call and webcast at 5:00 p.m.

Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue. Nine-episode inaugural season hosted by industry thought leader Melissa K.

Bausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, improved profitability, and management's commitment to debt reduction and strategic portfolio development. Despite a heavy debt load, refinancing progress and upgraded 2025 guidance support my thesis of undervaluation and a 27% upside to $9.1 per share.

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, and CUPERTINO, Calif. , Sept. 11, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire DURECT Corporation ("DURECT").

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, AND CUPERTINO, CA / ACCESS Newswire / September 11, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire DURECT Corporation ("DURECT"). Under the terms of the agreement, Bausch Health acquired all outstanding shares of DURECT for $1.75 per share in cash, representing a total upfront cash payment of approximately $63 million at closing.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the American Journal of Ophthalmology has published results of the pivotal U.S. clinical trial of the enVista Envy novel full visual range intraocular lens. The study compared visual, refractive and patient-reported outcomes following implantation of enVista Envy and the enVista® monofocal IOL in cataract s.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-initiated study which evaluated the effectiveness of XIIDRA (lifitegrast ophthalmic solution) 5% in alleviating end-of-day (EOD) eye dryness and discomfort in symptomatic contact lens (CL) wearers.* XIIDRA is a prescription eye drop used to treat.

LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, today announced that the Company's proven Thermage technology has successfully been used to perform more than 5 million skin tightening and smoothing treatments. Thermage utilizes monopolar radiofrequency energy that can safely heat layers of skin and stimulate collagen production, naturally.